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Feasibility of cytological specimens for ALK fusion detection in patients with
advanced NSCLC using the method of RT 
Introduction
Precision medicine has come into reality for patients with advanced non small cell lung cancer(NSCLC) since epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or anaplastic lymphoma kinase(ALK) inhibitors has showed dramatic response in these with EGFR mutation or ALK fusion respectively [1] [2] [3] [4] [5] . Therefore, the detection of driver genes mutation status becomes essential to guide therapeutic decision in clinical practice.
As for ALK fusion detection, several methods have been developed, including fluorescent in situ hybridization (FISH), immunohistochemistry(IHC) and reverse transcriptase polymerase chain reaction(RT-PCR). FISH is the first accompanied diagnostic assay
approved by the FDA. Recently, Ventana IHC has also been approved by FDA since it showed a high consistency with FISH. However, both methods require relatively good quality specimen that contains sufficient cellular contents (e.g. nuclei number for FISH and protein level for IHC, etc.) for analysis. Therefore, histological tissue is preferred over cytological specimen. While, in clinical practice, patients with advanced stage NSCLC are unsuitable for radical surgery or biopsy. Thus, cytological samples were the major specimens to undergo molecular testing. For example, a survey from Asia showed that cytological samples were used to detect EGFR mutation status in as high as 50% of NSCLC patients [6] . Cell block could act as a complementary source of cytological specimens for FISH/IHC [7] [8] [9] [10] , while not all cytological cell blocks can be made successfully. In Sanz-Santos et al's study, less than 50% aspirates from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA )could be made into cell blocks and only 37.6% of them contained diagnostic material [11] .
RT-PCR, another alternative ALK fusion diagnostic assay, is rapid and convenient to perform and can be readily applied to cytological specimens such as bronchial washing fluid or pleural effusion that may not be suitable to be prepared as paraffin-embedded blocks [12] . Our previous study together with Rosell's showed that the incidence of EML4-ALK fusion was higher when detected by RT-PCR compared to IHC or FISH analysis [13, 14] . In this regard, the Chinese Food and Drug Administration has approved ADx EML4-ALK fusion gene diagnostic kit to be used to detect ALK fusion, and this particular assay has also been accepted by Chinese Anti-Cancer Association [15] [16] [17] [18] .
However, up to now, it is still unknown whether we can use cytological specimen for RT-PCR to detect ALK fusion and achieve comparable value in clinical decision. In addition, there is no data has ever addressed the best source and quality criteria of the cytological specimen for this RT-PCR approach.
Aim to evaluate the feasibility of cytological samples to detect ALK fusion status with the method of RT-PCR, we compared RNA yields and the incidence of ALK fusion between cytological specimens with tumor tissues in 1274 patients with advanced NSCLC.
Moreover, we compared the efficacy of crizotinib in patients with ALK fusion according to different types of specimen. Progression-free survival (PFS) was defined as the time interval from the first day of treatment to documented disease progression or death of any cause. Adverse events were assessed and classified according to national cancer institute common terminology criteria for adverse effects (CTCAE version 4.0). This study was approved by the ethics committee of Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, and a written informed consent was obtained from each participant before the initiation of any study-related procedure.
Method

Specimen preparation and RNA extraction
For all cytology specimen obtained via FNA, one part was sent to the pathologists, whereas another part was immediately placed in an RNase-free Eppendorf tube containing 500μl of RNA later (Cat No.AM 7021, life technologies) and stored at -20°C
. Once the specimen was confirmed by our pathologists to have tumor cells of more than 50, the RNA later preserved part will be taken out to extract mRNA. For sputum samples, at least 50 tumor cells were confirmed by liquid-based cytology test before it was preceded to mRNA extraction. For effusion specimen, ~50 to 1200ml of tumor containing effusion was centrifuged at 2,500 rpm for 3 minutes to achieve a cell pellet, which was then incubated with erythrocyte lysate for 10 minutes. This mixture was centrifuged again at 2500 rpm for 3 minutes and the resultant cell pellet was re-suspended in normal saline solution before RNA extract. While tumor tissues were stored in the formalin-fixed, paraffin-embedded (FFPE) blocks until use. No less than 5 slides were collected for RNA extraction as mentioned above. Either RNeasy Mini Kit (Qiagen, Hilden, Germany) or AmoyDx RNA Kit (Amoy Diagnostics Co, Xiamen, China) was used to extract mRNA, which was subsequently quantitated by NanoDrop 2000
Spectrophotometer (Thermo Scientific, Waltham, USA).
ALK fusion Detection
ALK fusion were detected AmoyDx EML4-ALK Fusion Gene Diagnostic Kit (Cat No.
ADx-FF04, Amoy Diagnostics Co, Xiamen, China). In brief, the mRNA extracted from the previous step was reverse transcribed to cDNA at 42°C, followed by PCR denotes ALK. The fluorescence signal released from the PCR products was used to determine the amplification cycles (Ct) needed. Assay reactions requiring Ct values of ≤30 cycles were considered positive for one of the ALK fusion. The details can be referred to our previous studies [13, [19] [20] [21] [22] . To reduce the false positive, we sequenced the 21 known variants to confirm ALK fusion for the first 20 patients and then every 3 patients with ALK RT-PCR positive fusion.
Statistical analysis
All of the statistical tests were performed using the SPSS 
Discussion
As far as we know, this study was the first one to investigate the feasibility of ALK fusion detection in a large scale of cytological samples with the method of RT-PCR. We compared the RNA yield in 1002 advanced NSCLC patients with cytological specimens with 272 with tumor tissue and found the average RNA concentration was 60.99 ng/μl in cytological sample, which was similar as 63.16 ng/μl (p=0.727) in tumor tissue. Also, the incidence of ALK fusion is similar (8.3% vs 9.2%, P=0.624) in the both group. What's more, both groups showed a similar efficacy of crizotinib regarding to ORR and mPFS.
Taken together, cytological specimens are feasible and should be recommended for ALK fusion detection by RT-PCR in patients of advanced NSCLC.
The implementation of precision medicine depends on the acquisition of tumor cells for driver mutation analysis. A survey on EGFR mutation detection in Asia showed that patients with cytological samples contributed as high as 50% of the whole population who had undergone EGFR mutation testing [6] , suggesting that cytological samples was the main source for molecular analysis in clinical practice. Our previous study also found that EBUS guided needle aspiration provide sufficient tumor cell for multiple biomarker testing such as EGFR mutation, ERCC1, RRM1 and BRCA1 mRNA expression [23] .
However, comprehensive analysis cytological samples such as pleural effusions, fine needle biopsy and so on to perform ALK fusion testing is still unknown. In this study, we found that cytological samples provides similar RNA yield as lung cancer tissues in patients with NSCLC (60.99 ng/μl vs.63.16 ng/μl,p=0.727). Furthermore, we compared the RNA yields in cytological subgroups and found that it was higher in the malignant effusions than needle aspiration sample group, potential explanation might be that the cancer cells were collected by repeatedly centrifuged in amount of effusions. Moreover, we investigated the association of RNA concentration with ALK fusion status and found that the minimum RNA concentration was 1.16ng/μl in ALK positive patient. This patient received a TTNA and the sequencing result showed EML4-ALK fusion type of E13;A20.
He experienced partial response after the treatment of crizotinib with a PFS of 5.43 months, which indicated that RT-PCR is sensitive and has a low requirement for the cytological testing samples.
Currently, FISH, Ventana IHC and RT-PCR are three approved and recommended methods for ALK fusion detection. Among them, RT-PCR is free from subjective bias in analysis and can be readily applied to cytological specimens [12, 24] . Several studies have demonstrated that there is a high concordance between the RT-PCR with FISH or IHC [13, 14, [25] [26] [27] [28] [29] . In our previous study, we compared RT-PCR with FISH to detect ALK fusion in 255 patients and revealed a concordance rate of 99.2% [13] . Thus, RT-PCR was selected as the ALK fusion detection method in this study. We found the incidence of ALK fusions was 8.3% (83/1002) in patients with cytological specimens, which was similar to patients with tumor tissue (9.2%,25/272, p=0.624) and also was in the range of incidence that previous reported in the Asian NSCLC population [30] [31] [32] [33] [34] [35] . The frequency seems to be higher than that in Caucasian population, part of the explanation was that a part of patients was selected as EGFR wild population. Our previous study has shown that the frequency of ALK fusion could be as high as 32.3% among selected patients who have never smoked and had adenocarcinoma harboring wild-type EGFR [19] . The ALK fusion were associated with a younger age, female, non-smoker and adenocarcinoma, which were consistent with previous studies [33, 36, 37] . As for efficacy evaluation, no significant differences were found regarding to both ORR (62.0% vs.42.1%, p=0.177) and mPFS [8.6 months (95% CI 7.30-9.84) vs7.0 months (95% CI 4.54-9.47) ,p=0.736] after the crizotinib treatment in cytological group and tissue group. The mPFS in the whole population was 8.4 months (95% CI 6.41-10.39), which was fell in the range of 7.7 to 10.9 months as shown in the relevant phase I to III clinical trials [5, 38, 39] .
As the first large-scale study, our study has several limitations. Firstly, this was a retrospective study with selected groups of patients, which could have inevitably induced a selection bias. For example, there were more patients with adenocarcinoma and some already had known wild type EGFR. Secondary, the lack of a comparison with cell block and further validation by other detection methods, such as FISH and IHC made our less convictive. On the other hand, the observational nature of this study made our results more reproduceable in the real-world. Thirdly, although we had a large population of patients with cytological sample (n=1002 patients), the sputum and subcutaneous nodules samples were relatively small. Thus, the finding of this article could not be generalized into these subpopulations.
In conclusion, our results showed that cytological specimens had a high feasibility to perform ALK fusion status detection by RT-PCR, which might be regarded as feasible sample source for ALK detection in patients of advanced NSCLC.
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